Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
May 12, 2026 9:01 AM EDTPooled post hoc analysis of GATHER1 and GATHER2 showed IZERVAY® (avacincaptad pegol intravitreal solution) reduced the risk of progressing to loss of driving eligibility compared with sham over 24 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Encore GATHER2 open-label extension data demonstrated IZERVAY was well-tolerated, with no new safety signals, and earlier intervention with IZERVAY resulted in slowing GA with greater protection of healthy retinal tissue
NORTHBROOK, Ill.,... More
